Singapore: AstraZeneca's global biologics R&D arm, MedImmune, plans to acquire Amplimmune, which is a US-based biolo...
Singapore: Biostar Pharmaceuticals, a China-based manufacturer and marketer of pharmaceutical and health supplement prod...
Singapore: Japan-based Otsuka Pharmaceutical and H Lundbeck have received US FDA approval for Abilify Maintena (aripipra...
Singapore: Australia-based Novogen has acquired a novel drug technology that will be developed as a potentially major cl...
Singapore: US Food and Drug Administration (FDA) have issued a complete response letter regarding a supplemental New Dru...
Singapore: Sanofi and the Global Alliance for TB Drug Development (TB Alliance) entered a research collaboration to acce...
Lupin Pharmaceutical, which aims to be the best transnational pharmaceutical company in the world, stroked 10.64 percent...
Singapore: Australian drug delivery technology company Phosphagenics has appointed biotech industry veterans Mr Lawrence...
Singapore: Following successful first-in-man phase I and two phase IIa clinical studies with the oral formulation of fin...
Recent promising data on drug approvals in 2011 shows that there were 35 new molecular entities (NME) approved by the FD...
Singapore: Sweden-based Medivir has discontinued the development of its hepatitis B compound MIV-210 based on a joint de...
Singapore: Eisai revealed its preliminary results from a recently completed phase III study of Halaven versus capecitabi...
Singapore: A study by researchers at the University of Michigan Medical School, US, found that antidepressant drug trany...
Singapore: Australian pharmaceutical company Pharmaxis is all set to launch Bronchitol for cystic fibrosis (CF) patients...
Singapore: UK's Marvel LifeScience, insulin marketing company, has withdrawn its application for centralized marketing a...
Singapore: Alchemia has completed enrollment of patients in a pivotal phase III clinical trial evaluating its lead prod...
Sinapore: Bayer HealthCare in Singapore in collaboration with five research institutions have kaunched new Integrated Tr...
Singapore: Daiichi Sankyo's 24-month randomized, double-blind, placebo-controlled multi-center phase III clinical trial ...
